Clinical characteristics and chemotherapy efficacy in patients with newly diagnosed multiple myeloma: observation of 176 cases

Abstract

Objective To investigate the clinical characteristics and treatment efficacy in newly diagnosed multiple myeloma (MM). Methods The clinical data and treatment methods of 176 patients with newly diagnosed MM were retrospectively analyzed. Results The most common chief complaint in the patients with MM was bone pain. 26.1% (46/176) patients once experienced misdiagnosis. The overall response rate (ORR) was 65.9% (116/176), the ORR of bortezomib group (81.0%, 34/42) was significantly higher than that of M2 regimen group (61.8%, 34/55) and VAD regimen group(60.8%, 48/79) (P 0.05). The most common adverse reactions included hematologic toxicity, infection and peripheral neurotoxicity. Multiple organ failure was the main cause of death (47.1%, 16/34). Conclusions The clinical manifestations of MM are complex and diverse, which is easy to be misdiagnosed. Molecular genetic abnormalities are closely related to prognosis. Proteasome inhibitor bortezomib can improve the curative effect and not be affected by renal function. To prolong the survival time of the patients needs to prevent and control the infection and renal insufficiency actively. Key words: Multiple myeloma; Clinical characteristics; Treatment outcome